Amoxycillin 200MG with Clavulanic Acid 28.50 MG Dry Syrup Drug Information Amoxycillin 200mg with Clavulanic Acid 28.50 Mg Dry Syrup is an oral dry powder formulation that has to be dissolved in a specified amount of water to produce a uniform liquid suspension. For formulation that contain more than one active pharmaceutical agent, everything from powder blending, moisture content, particle properties and re-dispersibility behavior must be given the attention required. For pharmaceutical companies that want to establish a wider product range, this dosage form can be part of a professionally managed PCD Pharma Franchise portfolio with appropriate packaging and quality systems.
Dry syrup manufacturing, in contrast to ready-to-use liquid, must formulate to maintain physical stability in dry form and disperse properly upon reconstitution. As a result, powder engineering, accurate filling of bottles and moisture resistant packaging are key stages of development.
The process of making this formulation starts with evaluation of the physical properties of amoxycillin and clavulanic acid as well as those of the excipients chosen. The physical properties include particle size, density, moisture activity and flow properties.
The excipients are chosen based on their technological function in the dry syrup. They may affect powder flow, suspension, palatability, viscosity, wetting or physical stability after reconstitution. The formulation should allow for the right ratio of the two actives to be present, while still being amenable to manufacture and filling.
For dry syrups particularly susceptible to environmental moisture, handling during manufacture is under controlled conditions. Raw materials are accurately weighed as per approved formulations and exposure of materials is limited, as per the formulation's requirements.
The complete manufacturing process also takes into account the homogeneous distribution of the two active ingredients. It is essential that the two ingredients stay sufficiently separated in the dry powder so that the final finished product contains the active ingredients in the correct ratio.
Formulation processing may consist of sieving, conditioning of particle-size distributions, prelanding and final blending in a controlled manner, all depending on the formulation design. The order of addition is relevant when ingredients have significantly different sizes or densities.
Mixing specifications are defined at formulation development and retained in commercial manufacturing. Blend samples can be removed from specific locations and tested by validated analytical methods. These sampling points serve as assurance that the powder has reached the specified level of uniformity prior to filling.
Transfer of powder has to be handled with care, as vibration, motion or rough handling can cause segregation. Manufacturing controls therefore have to go beyond the blender and include transfer and filling.
The most important feature of dry syrup can be observed after reconstitution. After following the addition of the prescribed amount of water, the powder should be evenly dispersed and ready for appropriate suspension characteristics defined during the formulation development.
Wetting and dispersion effects depend on particle size, excipient and physical form of the powder. It is possible to assess the product for effects such as ease of reconstitution, shotting, and the ability to disperse after shaking over the intended time period of use.
Parameters like viscosity and sedimentation characteristics may also be taken into account if appropriate to the formulation. The consistence of the suspension can be influenced by too rapid the settling or by poor responsibility.
The final fill volume is also determined accurately because the powder must contain the correct concentration when reconstituted. Manufacturing and quality-control steps are performed to ensure that the powder fill does not vary from bottle to bottle.
Moisture management may be critical for dry syrup products, and manufacturing facilities, equipment, and packaging materials may need to be kept under specified environmental conditions to minimize avoidable moisture exposure during processing.
The powders are measured during bottle filling with relevant in-process checks. Changes in fill-weight, the condition of powders, and the cleanliness and seal performance of bottles, can all be measured as part of routine manufacturing controls.
Finished-product testing can cover the identification and assay of active ingredients, as well as relevant powder content uniformity and other specific characteristics of the product's formulation. Additional tests may be done after product reconstitution based on the FDA's approved specific.
The analytical procedures must demonstrate good discrimination of amoxycillin and clavulanic acid. The raw-material and processing information, as well as in-process results and finished-product testing gives a complete record of each batch.
Packaging is also important in protecting dry syrup formulations. Appropriate pharmaceutical bottle and closure combination can help maintain the dry powder state throughout the storage. Based on the final formulation and specification, the moisture-protective packaging elements could also be included.
Enough room for product identification, batch, manufacturing and – if necessary – reconstitution instructions should be available in the container. Closure integrity is checked during the packaging development process to minimize unneeded contact with the environment.
Stability testing To demonstrate that the formulation maintains the desired quality characteristics throughout storage, the dry powder and reconstituted suspension may be tested in accordance with the relevant stability protocol.
Pharma Franchise Product Range For firms adding to their pharmaceutical portfolio, Amoxycillin 200MG with Clavulanic Acid 28.50 MG Dry Syrup can be within an organized PCD Pharma Franchise range. Repeated manufacturing, humidity aware packaging, specified reconstitution features and professional product packaging can help in an organized range of portfolio.
In general, the formulation for this dry syrup product needs the careful balancing of powder process, blending of both actives, continuous exposure to moisture, fill quantity control, reconstitution effectiveness, quality assurance tests, and packaging. Having a specified control throughout the process would enable a reproducible finished product and pharmaceutical process.
Amoxycillin 200mg Clavulanic Acid 28.5mg Dry Syrup covering formulation, reconstitution, quality testing, stability and PCD Pharma details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech